Vanadis NIPT Basic

Vanadis NIPT Basic package

This test screens for abnormalities in 5 key chromosomes, including:

• Trisomy 21 (Down syndrome)
• Trisomy 18 (Edwards syndrome)
• Trisomy 13 (Patau syndrome)
• Sex chromosome abnormalities (X and Y)

The estimated turnaround time for results is approximately 7 days after the laboratory receives the sample.

 

The Vanadis NIPT Basic test screens for fetal chromosomal abnormalities using Rolling Circle Replication (RCR) technology. This technology increases the amount of cell-free fetal DNA (cffDNA) present in the mother's blood. Specific probes targeting chromosomes 13, 18, 21, X, and Y are then used to directly count the number of chromosomes from the fetal DNA.

This method analyzes a blood sample from the mother, therefore amniocentesis is not required, and no additional risk is posed to the fetus. The test also demonstrates high accuracy of more than 99%, with a false-positive rate of approximately 0.14% for Down syndrome screening.

RCR system operates based on direct molecular counting of DNA molecules rather than using DNA sequencing technology such as Next-Generation Sequencing (NGS). Enzymes are used to fragment DNA from the chromosomes of interest (such as 13, 18, 21, and the sex chromosomes). These fragments are then labeled with fluorescent markers, and the signals are counted and compared with reference chromosomes to assess the risk of chromosomal abnormalities.

Although both RCR and NGS are NIPT methods that analyze maternal blood samples and can screen for the risk of Trisomy 13, 18, 21, as well as sex chromosome abnormalities (X and Y), the Vanadis system involves simpler laboratory procedures, less complex data analysis, and may offer shorter turnaround times for results.

However, in general, RCR testing focuses primarily on screening major chromosomal abnormalities, and therefore its scope of detection may be more limited compared with NGS-based testing, which can expand screening to additional genetic abnormalities in certain testing panels.